SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 May 27

PMID 37240080

Authors

Assunta Di Costanzo

Giovanni Esposito

Ciro Indolfi

Carmen Anna Maria Spaccarotella

Affiliations

Soon will be listed here.

Abstract

The purpose of this manuscript is to review the effects of sodium-glucose cotransport protein 2 inhibitors (SGLT2is) in patients with chronic kidney disease according to basic mechanisms, current recommendations, and future perspectives. Based on growing evidence from randomized, controlled trials, SGLT2is have proven their benefit on cardiac and renal adverse complications, and their indications expanded into the following five categories: glycemic control, reduction in atherosclerotic cardiovascular disease (ASCVD), heart failure, diabetic kidney disease, and nondiabetic kidney disease. Although kidney disease accelerates the progression of atherosclerosis, myocardial disease, and heart failure, so far, no specific drugs were available to protect renal function. Recently, two randomized trials, the DAPA-CKD and EMPA-Kidney, demonstrated the clinical benefit of the SGLT2is dapagliflozin and empagliflozin in improving the outcome in patients with chronic kidney disease. For the consistently positive results in cardiorenal protection, the SGLT2i represents an effective treatment to reduce the progression of kidney disease or death from cardiovascular causes in patients with and without diabetes mellitus.

Citing Articles

Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review.

Bombonato M, Beccuti G, Benso A, Giannone B, Bertaina S, Broglio F Hormones (Athens). 2025; .

PMID: 39903441 DOI: 10.1007/s42000-025-00632-8.

Comment on "SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect".

Peronard R, Mayntz S Am J Cardiovasc Drugs. 2024; 25(1):129-130.

PMID: 39680272 DOI: 10.1007/s40256-024-00706-9.

Effects of canagliflozin on brain natriuretic peptide levels in patients with type 2 diabetes on peritoneal dialysis in Japan: protocol for a multicentre, prospective, randomised controlled trial (CARD-PD trial).

Matsuoka N, Nakazawa D, Nishio S, Cho K, Maoka T, Kaneshima N BMJ Open. 2024; 14(11):e084846.

PMID: 39592158 PMC: 11590846. DOI: 10.1136/bmjopen-2024-084846.

Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease.

Frak W, Dabek B, Balcerczyk-Lis M, Motor J, Radzioch E, Mlynarska E Antioxidants (Basel). 2024; 13(6).

PMID: 38929126 PMC: 11200916. DOI: 10.3390/antiox13060687.

Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India.

Jain P, Guha S, Kumar S, Sawhney J, Sharma K, Sureshkumar K Cardiol Ther. 2024; 13(2):243-266.

PMID: 38687432 PMC: 11093928. DOI: 10.1007/s40119-024-00367-4.

References

Takagi S, Li J, Takagaki Y, Kitada M, Nitta K, Takasu T . Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J Diabetes Investig. 2018; 9(5):1025-1032. PMC: 6123054. DOI: 10.1111/jdi.12802. View

Zelniker T, Braunwald E . Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018; 72(15):1845-1855. DOI: 10.1016/j.jacc.2018.06.040. View

Skrtic M, Cherney D . Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2014; 24(1):96-103. DOI: 10.1097/MNH.0000000000000084. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Heerspink H, Perco P, Mulder S, Leierer J, Hansen M, Heinzel A . Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019; 62(7):1154-1166. PMC: 6560022. DOI: 10.1007/s00125-019-4859-4. View

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

Alshnbari A, Millar S, OSullivan S, Idris I . Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies. Diabetes Ther. 2020; 11(9):1947-1963. PMC: 7434811. DOI: 10.1007/s13300-020-00885-z. View

Trum M, Riechel J, Lebek S, Pabel S, Sossalla S, Hirt S . Empagliflozin inhibits Na /H exchanger activity in human atrial cardiomyocytes. ESC Heart Fail. 2020; 7(6):4429-4437. PMC: 7755005. DOI: 10.1002/ehf2.13024. View

Anker S, Butler J, Filippatos G, Ferreira J, Bocchi E, Bohm M . Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385(16):1451-1461. DOI: 10.1056/NEJMoa2107038. View

10.

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E . Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013; 159(4):262-74. DOI: 10.7326/0003-4819-159-4-201308200-00007. View

11.

Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387(12):1089-1098. DOI: 10.1056/NEJMoa2206286. View

12.

Indolfi C, Barilla F, Basile C, Basso C, Cantaluppi V, Capasso G . [Italian Society of Cardiology-Italian Society of Nephrology Consensus document: The cardio-renal interaction in the prevention and treatment of cardiovascular diseases - Part II: From preventive strategies to treatment of patients with cardio-renal...]. G Ital Cardiol (Rome). 2022; 23(10):793-812. DOI: 10.1714/3881.38645. View

13.

van Bommel E, Muskiet M, Tonneijck L, Kramer M, Nieuwdorp M, van Raalte D . SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. Clin J Am Soc Nephrol. 2017; 12(4):700-710. PMC: 5383382. DOI: 10.2215/CJN.06080616. View

14.

Fitchett D, Zinman B, Wanner C, Lachin J, Hantel S, Salsali A . Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016; 37(19):1526-34. PMC: 4872285. DOI: 10.1093/eurheartj/ehv728. View

15.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

16.

Packer M, Anker S, Butler J, Filippatos G, Ferreira J, Pocock S . Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2020; 143(4):326-336. PMC: 7834905. DOI: 10.1161/CIRCULATIONAHA.120.051783. View

17.

Sabatino J, De Rosa S, Tamme L, Iaconetti C, Sorrentino S, Polimeni A . Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020; 19(1):66. PMC: 7229599. DOI: 10.1186/s12933-020-01040-5. View

18.

Simone S, Chieti A, Pontrelli P, Rascio F, Castellano G, Stallone G . On-line hemodiafiltration modulates atherosclerosis signaling in peripheral lymphomonocytes of hemodialysis patients. J Nephrol. 2021; 34(6):1989-1997. PMC: 8610953. DOI: 10.1007/s40620-020-00958-z. View

19.

Santer R, Calado J . Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2009; 5(1):133-41. DOI: 10.2215/CJN.04010609. View

20.

Harrington J, Udell J, Jones W, Anker S, Bhatt D, Petrie M . Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J. 2022; 253:86-98. DOI: 10.1016/j.ahj.2022.05.010. View